Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Inhaled LAMELLASOME™ treatment period has the potential to halt or reduce the severity of the disease progression of COVID-19 patients to requiring scarce critical care resource.
Lead Product(s): Lamellasome COVID-19 therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2020